HealthDay - MONDAY, May 23 (HealthDay News) -- U.S. Food and Drug Administration approval of Sutent (sunitinib) has been expanded to include people with neuroendocrine pancreatic cancer that is inoperable or has metastasized to other parts of the body.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.